A Phase 1 Open Label Dose-Escalation and Expansion Study of Oral ORIN1001 with and without Chemotherapy in the Treatment of Subjects with Solid Tumors

Brief description of study

The purpose of the study is to determine the recommended Phase 2 dose of ORIN1001 when given as a single agent as well as phase 2 dose of daily ORIN1001 in combination with Abraxane® for individuals with relapsed refractory metastatic breast cancer (TNBC or ER+ HER2-). The study drug ORIN1001 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.

Clinical Study Identifier: s20-01664
ClinicalTrials.gov Identifier: NCT03950570

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.